Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.31 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056769 | 0.85 | IMPDH2 (0.37) | LMNAGAAKDM4EALDH1A1MAPT | |
| SCHEMBL14873787 | 0.77 | RXFP1 (0.36) | RXFP1PKMPARP1HTR6PRNP | |
| SCHEMBL1343517 | 0.77 | IMPDH2 (0.52) | GAAKDM4EALDH1A1MAPTSLC22A12 | |
| SCHEMBL198796 | 0.77 | RXFP1 (0.48) | RXFP1PKMPARP1HTR6PRNP | |
| SCHEMBL30710586 | 0.77 | RXFP1 (0.48) | RXFP1PKMPARP1HTR6PRNP | |
| SCHEMBL29429114 | 0.77 | RXFP1 (0.48) | RXFP1PKMPARP1HTR6PRNP | |
| SCHEMBL1227243 | 0.75 | CA1 (0.38) | ALDH1A1CYP1A2 | |
| SCHEMBL9035492 | 0.74 | IMPDH2 (0.53) | GAAKDM4EALDH1A1MAPTSLC22A12 | |
| SCHEMBL3251429 | 0.73 | ALDH1A1 (0.36) | L3MBTL1FABP4NPSR1GAAKDM4E | |
| SCHEMBL9670876 | 0.73 | CYP2A6 (0.59) | RXFP1PKMLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743061-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | Pascal Biosciences Inc. (CA) | 2020-12-02 | — | — | EP | claimed |
| WO-2019144126-A1 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | PASCAL BIOSCIENCES INC. (CA) | 2019-07-25 | — | — | WO | claimed |
| WO-2020153758-A1 | COMPOSITION, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | 엘티소재주식회사 | 2020-07-30 | — | — | WO | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| WO-2015099508-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | 희성소재(주) | 2015-07-02 | — | — | WO | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-6610848-B1 | Platinum 1,2-enedithiolates; L2Pt(S2C2(2-pyridine)(H) wherein L2 is bis(diphenyldiphoshino)methane (dppm), 1,2-bis(diphenyldiphosphino)ethane (dppe) or 1,3-bis(diphenyldiphosphino)propane (dppp) | LUMET LLC | 2003-08-26 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4154722-A | PHOTOSTABILITY | CIBA-GEIGY CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | CBR3, CYP51A1, CYP8B1 | RXFP1 1392/4885PKM 1989/4885PARP1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.